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INTRODUCTION
Follicular fluid has an important role in the physiology of follicular growth, oocyte maturation, and ovulation. Ovulation in mammals is preceded by rapid follicle expansion under constant hydrostatic pressure [1] . This expansion is due to an increase in the proteolytic enzyme activities in ovulatory follicles [2] [3] [4] and an increase in vascular permeability [5] . Follicular fluids are composed of exudates from plasma through the follicular epithelium and secreted products of the follicle, especially granulosa cells. The fibrinolytic system is involved in ovulatory processes [2] [3] [4] . However, limited information is available regarding the possible role of the coagulation system in mammalian ovu- lation. Yamada and Gentry [6] examined the hemostatic profile of bovine ovarian follicular fluid and found that the levels of fibrinogen and factor X were approximately 2-fold lower and the levels of factor VII were approximately 10-fold lower than those in plasma. They also found no functional intrinsic coagulation factors in the fluid. Specifically, they noted the absence of factor VIII and extremely low levels of factors IX and XI. The presence of sulfated proteoglycans in ovarian follicular fluid has been described in various animals, including cow [7] [8] [9] , pig [10] [11] [12] , sheep [13] , horse [14] , and rat [15] [16] [17] . The proteoglycans in the follicular fluid have been theorized to maintain the viscosity of the fluid in the extended follicles during follicular maturation [15] . Moreover, the sulfated proteoglycans in the follicular fluid from these animals may cause hypocoagulablity by binding with antithrombin [12, 14, 16] . In humans, the roles of proteoglycans in the fluid have been discussed in relation to cumulus expansion, fertilization, and development [18] . However, there have been no previous reports about inhibitors of the coagulation pathway such as tissue factor pathway inhibitor (TFPI), protein C, and protein S. TFPI inhibits the extrinsic coagultion pathway, inhibiting both factor VIIa/tissue factor complex and factor Xa [19] . Protein C is activated on the surface of endothelial cells by thrombin bound to thrombomodulin. Together with its cofactor, protein S, activated protein C catalyzes the proteolytic degradation of the membranebound thrombin-activated forms of coagulation factors V and VIII (Va and VIIIa).
Little is known about human follicular fluid in terms of the functional interaction of the coagulation pathway, although protein concentrations in the fluid have been compared with those in plasma [10, [20] [21] [22] [23] . This study was performed to determine the level of coagulablity in human follicular fluid. The mechanisms responsible for this hypocoagulable state also were investigated.
MATERIALS AND METHODS

Materials
The following materials were commercially available: BSA (Boehringer Mannheim Biochemica, Tokyo, Japan), bovine fibrinogen type 1 (Daiichi Pure Chemicals, Tokyo, Japan), human thrombin (250 U/mg; Protogen AG, Laufelfingen, Switzerland), fluorogenic peptide substrates for thrombin (Boc-Val-Pro-Arg-4 methylcoumarin-7-amide [Boc-Val-Pro-Arg-MCA]) and for factor Xa (Z-Pyr-GlyArg-MCA) (Peptide Research Institute, Osaka, Japan), human factor Xa (Cosmo Bio, Tokyo, Japan), antithrombin (Anthrombin P; Behring, Marburg, Germany), heparinase, heparitinase, and chondroitinase ABC (protease free) (Sei-kagaku Kogyo, Tokyo, Japan), Superdex 200 HR (1.6/60; Pharmacia LKB Biotechnology, Uppsala, Sweden), and porcine intestine heparin (Sigma, St. Louis, MO). Heparin cofactor II (HCII) was kindly supplied by Dr. Hidetaka Nagase (Taiho Pharmaceutical Co., Tokushima, Japan). Human recombinant TFPI, which was prepared from Chinese hamster ovary cells as described previously [24] , was kindly supplied by Dr. Yu-ichi Kamikubo (Chemo-Sera-Therapeutic Research Foundation, Kumamoto, Japan).
Collection of Follicular Fluid and Blood
Seventeen samples of ovarian follicular fluid were obtained from preovulatory ovarian follicles of individual patients undergoing in vitro fertilization (IVF) treatment. The protocol for this study was approved by the Internal Review Board of Kobe City General Hospital. The IVF procedure outlined is routinely used throughout Japan. Written informed consent for the use of specimens was obtained from all patients. Pituitary suppression of these patients was performed by intranasal administration of the LH-releasing hormone analogue (Suprecur; Hoechst, Tokyo, Japan) at 900 g/day from Day 1. The subsequent follicular development was stimulated i.m. by human menopausal gonadtrophin (Fertinorm P; Serono, Tokyo, Japan) at 150 IU/day from Day 3 of the IVF cycle onward. All patients received 10 000 IU of hCG (Mochida, Tokyo, Japan) administered i.m. 36 h before follicle puncture. The follicular fluid was aspirated by transvaginal puncture using ultrasonic guidance. In all patients, fluid samples were recovered from more than one follicle, and samples were pooled before analysis. Granulosa cells were prepared from the fluid samples by Percoll centrifugation [25] . Nonfasting venous blood samples were taken within 5 min of starting the procedure. Both fluid and blood samples were mixed with 3.31% sodium citrate at a ratio of nine parts sample to one part sodium citrate. For follicular fluid, approximately 1 min was required for ovum recovery prior to mixing with sodium citrate.
Analysis of Coagulation Factors in the Follicular Fluid and Plasma
Ten of the samples without macroscopic blood contamination were used for analysis of coagulation factors. The following coagulation factors in the follicular fluids and plasma samples were estimated using enzyme immunoassay kits according to the manufacturers' instructions: tissue factor (TF) antigen, total and free TFPI antigens (ChemoSera-Therapeutic Research Foundation), protein C antigen (Iatron, Tokyo, Japan), protein S antigen (Teijin, Osaka, Japan), and thrombin-antithrombin complex (TAT) (Kokusai Shiyaku Co., Kobe, Japan). Fibrinogen and prothrombin were measured with commercial assay kits (Sankyo, Tokyo, Japan; Behring, Tokyo, Japan; respectively). Antithrombin activity was measured with an assay kit (Sankyo), using a chromogenic substrate. Protein C activity was measured with the Boehringer Mannheim assay kit. Activated partial thromboplastin time (APTT) (Platelin LS) and prothrombin time (PT) (Simplastin-Plus) reagents were purchased from Organon (Tokyo, Japan). Sulfated proteoglycans were measured with a Blyscan assay kit (Biocolor, Belfast, Northern Ireland) using chondroitin-4-sulfate suplied with the kit as a standard. HCII was measured with a kit (Stachrom HCII, Diagnostica Stago, Taverny, France). Antithrombin activity not affected by HCII was measured with a kit (Testzym-S antithrombinIII; Daiichikagakuyakuhin, Tokyo, Japan). The coagulation factors were measured in duplicate in each assay, and the mean values were used for analysis (Student t-test). The value of each factor group is shown as the mean Ϯ SD. To determine whether follicular fluid contained thrombin inhibitors, thrombin time was measured by mixing 100 l of the follicular fluid with 100 l of fibrinogen solution (2 mg/ml) and then with 100 l of various concentrations of thrombin solution. For comparison, normal pooled plasma or buffer alone was similarly mixed with fibrinogen and thrombin. We further determined activity of thrombin inhibitors in the follicular fluid by measuring thrombin activity, using a fluorogenic peptide substrate for thrombin after mixing thrombin (50 l, 0.625 U/ml) with serially diluted follicular fluid (150 l) in 50 mM Tris-HCl, pH 7.4, 0.15 M NaCl, and 0.1% BSA (300 l).
Gel Filtration of the Follicular Fluid
Follicular fluid (1 ml) was applied to a column (1.6/60 cm) of Superdex 200 HR equilibrated with 20 mM Tris-HCl buffer, pH 8.0, containing 0.15 M NaCl. Gel filtration was performed at a flow rate of 1 ml/min at room temperature, and 2-ml fractions were collected. Inhibition of thrombin activity by each fraction was measured by mixing 20 l of each fraction with 20 l of thrombin (0.25 U/ml) in 50 mM Tris-HCl, pH 7.4, containing 0.15 M NaCl and 0.1% BSA (total volume: 220 l). After 15 min of incubation at 37ЊC, the residual activity of thrombin was measured using a fluorogenic peptide substrate, Boc-Val-Pro-Arg-MCA, as reported previously [26] . PT and APTT in the follicular fluid were also measured after treatment with heparitinase. Follicular fluid (630 l) was mixed with serially diluted heparitinase (70 l). After 2 h at 37ЊC, 100 l of the mixture was mixed with 200 l of PT or APTT reagent.
Effects of Sulfated Proteoglycan Fraction on the Inhibitory Activities of Antithrombin, HCII, and TFPI
The effect on antithrombin was examined by mixing 20 l of fraction No. 22 (serially diluted), 20 l of antithrom- bin (1 U/ml), 20 l of thrombin (0.25 U/ml), and 360 l of 50 mM Tris-HCl, pH 7.4, containing 0.15 M NaCl and 0.1% BSA. The effect on HCII was examined by mixing fraction No. 22 (25-200 l) and 20 l of HCII (0.1 U/ml) in 250 l of 50 mM Tris-HCl, pH 7.4, containing 0.15 M NaCl, 0.1% BSA, and 100 l of thrombin. The residual thrombin activity was measured as described above. The effect on TFPI was examined by mixing 20 l of Z-Pyr-Gly-Arg-MCA (1 mM), 20 l of TFPI (40 g/ml), and fraction No. 22 (50-400 l) in 500 l of 50 mM TrisHCl, pH 7.4, containing 0.15 M NaCl, 0.1% BSA, and 5 mM CaCl 2 . After 20 min of incubation at 37ЊC, 800 l of factor Xa (7 nM) was added to the mixture. The MCA liberated was measured after 60 sec, as reported previously [24] .
Synthesis of Radiolabeled cDNA Probe for Human TFPI
The specific probes for human TFPI and human actin mRNA were produced by Megaprime DNA labeling systems (Amersham Pharmacia Biotech, Tokyo, Japan) using 32 P-labeled dCTP. The templates for the labeling system were produced by polymerase chain reaction (PCR). The plasmid pBSII [24] containing human TFPI cDNA and plasmid pUC18 containing the human beta-actin cDNA were used as the template for PCR. The primers for TFPI were 5Ј-CAGTGCGAAGAATTTATATATGG-3Ј (sense) and 5Ј-TTGCATTCTTCCAGTGTCTC-3Ј (antisense), corresponding to human TFPI cDNA nucleotide positions of 363-386 and 647-667 [27] , respectively. The primers for actin were 5Ј-ACACTGTGCCCATCTACG-3Ј (sense) and 5Ј-ACCGCTCATTGCCAATGG-3Ј (antisense), corresponding to human actin nucleotide positions 523-540 and 1029-1047 [28] , respectively. The PCR was performed in 50 l of reaction mixture containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , 50 M dNTP, 1 M primers, 2.5 units of Taq polymerase (TaKaRa, Biochemicals, Kusatsu, Shiga, Japan), and 0.6 ng of the template DNA. The thermal conditions were 35 cycles at 94ЊC for 1 min, 60ЊC for 1 min, and 72ЊC for 1 min.
RNA Preparation and Northern Blot Analysis of TFPI mRNA from Granulosa Cells
Human umbilical vein endothelical cells (HUVEC) (Clonetics, Walkersville, MD) were grown on 35-mm-diameter plastic dishes precoated with bovine collagen type I (Sumitomo Kagaku, Tokyo, Japan) in MCDB131 medium (Sigma), supplemented with 20 mM Hepes-NaOH (pH 7.4), 2% fetal bovine serum (Gibco BRL, Rockville, MD), and 10 ng/ml recombinant human basic fibroblast growth factor (R&D Systems, Minneapolis, MN). Total RNA was prepared from the cultured HUVEC and granulosa cells by the acid guanidium thiocyanate-phenol-chloroform method using ISOGEN (Wako Chemicals, Osaka, Japan) according to the manufacturer's protocol. The samples were electrophoresed in a 1.0% agarose gel containing 2.2 M formaldehyde. RNA in the gel was transferred onto a Gene Screen Hybridization Transfer Membrane (Dupont, Boston, MA) and hybridized with radiolabeled human TFPI cDNA as a probe. Autoradiography was carried out using an imaging plate on a bioimaging analyzer (model BAS-2000; Fuji Photo Film Co., Tokyo, Japan).
RESULTS
Coagulation Profile of Follicular Fluid: A Comparison with Plasma
Both APTT and PT of the follicular fluid were longer than 300 sec ( Table 1 ). The levels of both fibrinogen and prothrombin were about 45% of those in plasma. The levels of antigen for proteins C and S in the follicular fluid were 75% and 39% of the levels of their respective antigens in plasma. The activities of antithrombin and protein C manifested by the follicular fluids were 86% and 58% of their respective activities in plasma. As compared with the HCII activity exhibited by normal pooled plasma, three samples of follicular fluid showed 37%, 58%, and 136% HCII activity. There was a 3.7-fold higher level of TF and a 13-fold higher level of TAT in the follicular fluid than in plasma. Levels of total TFPI antigen and the free form of TFPI in the follicular fluid were 4.9-fold and 14.7-fold higher, respectively, than those in plasma. Figure 1 shows the results of Northern blot analysis of TFPI mRNA in granulosa cells in comparison with that in HUVEC. Granulosa cells expressed significantly higher levels of TFPI mRNA than did HUVEC. The thrombin clotting time of the follicular fluid was consistently prolonged, with thrombin at less than 3.33 U/ml, compared with that of normal pooled plasma or buffer alone (Table 2 ). After 5 min of incubation at 37ЊC, thrombin activity was inhibited by 200-fold diluted follicular fluid (data not shown).
Identification of the Thrombin Inhibitors in the Follicular Fluid by Gel Filtration
Although the follicular fluid showed strong thrombin inhibitor activity, none of the fractions eluted from a Super- (Fig. 2b) . When either fraction No. 22 or No. 40 was deleted from the complete mixture, thrombin inhibitor activity was lost (Fig. 2b) , but the deletion of other fractions did not affect the inhibitory activity of the mixture. The thrombin inhibitor activity of every other fraction was measured in the presence of fraction No. 22 (Fig. 3) . In fraction No. 40, there was a peak of thrombin inhibitor activity in the presence of heparin and the same peak of specific antithrombin activity without any other additions (data not shown). To examine whether fraction No. 22 contained a heparin-like substance, we measured its thrombin inhibitor activity after treatment with heparinase, heparitinase, or chondroitinase. The thrombin inhibitor activity of the treated fraction No. 22 samples in the presence of fraction No. 40 was almost completely lost following treatment with heparitinase, was partially lost by treatment with heparinase, but was not affected by treatment with chondroitinase (Fig. 4) .
Enhancement of Inhibitory Activities of Antithrombin, HCII and TFPI by Sulfated Proteoglycan in Fraction No. 22
We measured the concentrations of sulfated proteoglycan in the follicular fluid and fraction No. 22, using chondroitin sulfate as a standard. The values in three samples of follicular fluid were 93.4, 84.0, and 99.6 g/ml (equivalent to chondroitin sulfate standard). Thrombin inhibitor activity of antithrombin and HCII was measured, using fraction No. 22 containing 30 g/ml of sulfated proteoglycan. Thrombin activities in the presence of antithrombin and HCII decreased more with an increase in the concentration of sulfated proteoglycan in fraction No. 22 (Fig. 5a) , and there was a greater decrease in factor Xa activity as the concentration of sulfated proteoglycan in fraction No. 22 was increased in the presence of TFPI (Fig. 5b) . These results indicate that sulfated proteoglycan in fraction No. 22 enhanced anticoagulant activities of antithrombin, HCII, and TFPI.
PT and APTT of the Follicular Fluid after Treatment with Heparitinase
The prolonged clotting time of the follicular fluid may be due to the presence of a sulfated proteoglycan that is sensitive to heparitinase. PT and APTT were markedly shortened by the incubation of the follicular fluid with increasing amounts of heparitinase (Fig. 6 ).
DISCUSSION
The results of this study indicate that human follicular fluid is markedly hypocoagulable. Additional studies elucidated some potential mechanisms by which coagulation of the follicular fluid could be impaired. Tissue damage during ovulation may cause an increase in the levels of TF in follicular fluid. We detected a 3.7-fold higher level of TF and a 13.0-fold higher level of TAT in the follicular fluid than in plasma ( Table 1 ), suggesting that the extrinsic pathway of coagulation had been triggered. TAT has no effect on the coagulation pathway but can be used as an index of thrombin generation in vivo. The impaired coagulation in the follicular fluid could be due to suppression of the anticoagulant effect of thrombin by endogenous in-hibitory mechanisms. The thrombin clotting time was more prolonged by follicular fluid than by normal pooled plasma or buffer. We detected the activity of thrombin inhibitors in 200-fold diluted follicular fluid, using sensitive fluorogenic peptide substrate for thrombin. These results suggest that the follicular fluid may contain thrombin inhibitors that are responsible for retardation of clotting times. However, the levels of antithrombin and the coagulation factors in the protein C pathway in the follicular fluid were comparable to those in plasma (Table 1) .
In contrast, the levels of total TFPI and its free form were 4.9-fold and 14.7-fold higher than those in plasma, respectively. The increased level of TFPI was not due to another type of TFPI, TFPI-2 [29] , because the TFPI kit used in this experiment does not cross-react with TFPI-2 (S. Kamei and W. Kisiel, unpublished communication). Others have reported that TFPI is mainly synthesized by vascular endothelial cells [30] , partly by platelets [31] and macrophages [32] . The fact that TFPI antigen levels were markedly higher in follicular fluid than in plasma suggests that these factors are synthesized within the follicle. Granulosa cells expressed significant amounts of TFPI mRNA of two sizes, 1.4 and 4.0 kb, which was detected in cells that consistently expressed TFPI and arose from the use of alternative polyadenylation signals [33] . These findings suggest that TFPI may be a major suppressor of coagulation of the follicular fluid. Because TFPI can inhibit the extrinsic coagulation pathway, we expected that only low levels of TAT would be generated in the follicular fluid. However, there were large amounts of TAT in the follicular fluid, indicating that TFPI, although elevated, does not fully explain impaired coagulation in the follicular fluid.
To Heparin-like compounds are well known to accelerate antithrombin activity, and animal follicular fluids contain various types of proteoglycans, including chondroitin sulfate [7, 8, 11, 23] , heparan sulfate [7, 10, 11, 16, 23] , dermatan sulfate [10, 16] , and heparin-like glycosaminoglycans [13, 18] . Therefore, the relationship between fraction No. 22 and heparin-like compounds is of interest. Proteoglycans induced in fraction No. 22 were treated with the following three proteases: heparinase, heparitinase, and chondroitinase. Heparinase catalyzes eliminative cleavage of heparin and does not act on typical heparan sulfate. However, heparan sulfate including heparin-like structures may be cleaved by this enzyme. Heparitinase catalyzes eliminative cleavage of ␣-N-acetyl-D-glucosaminide linkage in heparan sulfate and does not act on heparin. However, heparin containing the above linkage may be cleaved by this enzyme. Chondroitinase ABC catalyzes the removal of chondroitin sulfate and dermatan sulfate side chains of proteoglycans. Because thrombin inhibitor activity of fraction No. 22 in the presence of fraction No. 40 was almost completely lost by treatment with heparitinase, was partially lost by treatment with heparinase, but was not affected by treatment with chondroitinase, fraction No. 22 seems to contain a sulfated proteoglycan, probably heparan sulfate. As shown in Figure 5a , fraction No. 22 indeed contained a sulfated proteoglycan, and there was a great increase in thrombin inhibitor activity of antithrombin as the concentration of sulfated proteoglycan in fraction No. 22 increased. These findings suggest that the anticoagulant activity of human follicular fluid may be due to the combination of at least two factors: a sulfated proteoglycan in fraction No. 22 and antithrombin in fraction No. 40. Based on the finding that rat granulosa cells synthesized proteoglycans [16, 17, 34, 35] , we speculated that human granulosa cells might also synthesize sulfate proteoglycan. HCII activity was also detected in follicular fluid. Although we did not analize the presence of HCII in fraction No. 40, we speculated that this fraction might include HCII because the molecular weight of HCII is similar to that of antithrombin. Because the complex between thrombin and HCII was not measured, the magnitude of the contribution of HCII is unclear.
PT and APTT in the follicular fluid were markedly shortened by the incubation of the fluid with increasing amounts of heparitinase. Others have reported that the concentrations of some coagulation factors in the follicular fluid are markedly low [6, 23] . However, the reduced concentrations of coagulation factors in the fluid may be an experimental artifact because sulfated proteoglycans in the fluid interfered with the shortening of the clotting time when activities of various coagulation factors were measured in the deficient plasma.
In this study, we demonstrated that there are substantial amounts of the free form of TFPI in the follicular fluid ( Table 1 ). The anticoagulant potency of TFPI is almost entirely restricted to its free form [36] . In human plasma, TFPI is mostly associated with lipoprotein (96%), whereas only 4% exists in free form [37] . One possible explanation for such a high concentration of the free form of TFPI in the follicular fluid is that the level of lipoprotein in the human follicular fluid is extremely low [38, 39] . Because proteoglycans can stimulate release of the free form of TFPI from the cell surface [40] , the existence of proteoglycans in the human follicular fluid would also explain why human follicular fluid contains substantial amounts of the free form of TFPI. TFPI does not appear to play a major role in the impaired coagulation properties of follicular fluid because of the presence of large amounts of TAT in the follicular fluid. Although TFPI may not have a major role, it may still contribute in some way to the overall hypocoagulability of the follicular fluid. One reason for the increase in TAT could be the unavoidable lack of anticoagulation during collection of the follicular fluid. Although the time interval was short (approximately 1 min), a significant amount of TAT complex could be formed. Another reason for the high levels of TAT could be the very slow generation of thrombin in the follicular fluid in contrast to that in circulating blood. Alternatively, TFPI may possess other functions than can influence coagulation.
Ovulation accompanied by tissue damage can cause an increase in the level of TF in follicular fluid, triggering the extrinsic coagulation pathway. However, it is necessary for follicular fluid to block the fibrin formation and maintain its fluidity until the release of the oocyte at ovulation. In this study, we demonstrated for the first time that the combination of proteoglycans, antithrombin, and possibly TFPI may play a major role in the hypocoagulability of human follicular fluid. We also demonstated that granulosa cells of the human preovulatory follicle synthesize substantial amount of TFPI. These findings will assist in improving our understanding of the mechanisms of the ovulatory process.
